Acasă › Mielom multiplu › Wisconsin › Milwaukee
Studii clinice pentru Mielom multiplu în Milwaukee, WI
21 studii pentru Mielom multiplu caută participanți în și în jurul orașului Milwaukee (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
În curs de recrutareFaza 3
- Research Site, Milwaukee
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
În curs de recrutareFaza 1/2
- Medical College of Wisconsin, Milwaukee
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 3
- Medical College Of Wisconsin, Milwaukee
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
În curs de recrutareFaza 4
- Froedtert Memorial, Milwaukee
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1/2
- The Medical College of Wisconsin, Milwaukee
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
În curs de recrutareFaza 2
- Aurora Cancer Care Milwaukee, Milwaukee
- Aurora St. Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- și încă 4
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
În curs de recrutareFaza 3
- Medical College of Wisconsin, Milwaukee
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
În curs de recrutareFaza 3
- Medical College of Wisconsin, Milwaukee
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1/2
- Research Site, Milwaukee
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
În curs de recrutareFaza 3
- Aurora Cancer Care-Milwaukee, Milwaukee
- Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee, Milwaukee
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus, Milwaukee
- și încă 13
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
În curs de recrutareFaza 1/2
- Research Site, Milwaukee
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
În curs de recrutareFaza 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
În curs de recrutareFaza 2
- MCW-Clinical Cancer Center at Froedtert Hospital Campus, Milwaukee
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
În curs de recrutare
- Medical College of Wisconsin, Milwaukee
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
În curs de recrutareFaza 3
- Froedtert Memorial Lutheran Hospital, Milwaukee
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
În curs de recrutareFaza 2
- Medical College of Wisconsin, Milwaukee
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
În curs de recrutareFaza 1
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
În curs de recrutareFaza 2
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
În curs de recrutareStudiu observațional
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Froedtert and the Medical College of Wisconsin, Milwaukee
Studii pentru Mielom multiplu în alte orașe
- New York City, NY60 studii
- Boston, MA42 studii
- Atlanta, GA41 studii
- Houston, TX38 studii
- Durham, NC37 studii
- Nashville, TN32 studii
- Denver, CO27 studii
- Rochester, MN24 studii
- St. Louis, MO24 studii
- Columbus, OH24 studii
- Baldwin Park, CA23 studii
- Chicago, IL22 studii
Alte studii în Milwaukee
- Cancer de sân23 studii
- Cancer pulmonar cu celule non-pătrate22 studii
- Cancer (toate tipurile)22 studii
- Cancer pulmonar21 studii
- Cancer de prostată20 studii
- Limfom folicular19 studii
- Cancer pancreatic18 studii
- Limfom non-Hodgkin18 studii
- Cancer ovarian17 studii
- Leucemie mieloasă acută17 studii
- Limfom Burkitt16 studii
- Insuficiență cardiacă16 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.